Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuroprotection.

K R Lees1

  • 1University Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow, UK.

British Medical Bulletin
|November 25, 2000
PubMed
Summary
This summary is machine-generated.

Neuroprotection offers a promising universal stroke treatment, alone or with thrombolysis. Despite past trial disappointments, ongoing research and improved trial designs enhance prospects for effective neuroprotective therapies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and outcomes of routine endovascular thrombectomy in large artery occlusion recorded in the SITS Register: An observational study.

Journal of internal medicine·2021
Same author

Small vessel disease and clinical outcomes after IV rt-PA treatment.

Acta neurologica Scandinavica·2017
Same author

Short runs of atrial arrhythmia and stroke risk: a European-wide online survey among stroke physicians and cardiologists.

The journal of the Royal College of Physicians of Edinburgh·2016
Same author

Cerebral small vessel disease, medial temporal lobe atrophy and cognitive status in patients with ischaemic stroke and transient ischaemic attack.

European journal of neurology·2016
Same author

Impact of heart rate on admission on mortality and morbidity in acute ischaemic stroke patients - results from VISTA.

European journal of neurology·2016
Same author

Determinants of post-stroke cognitive impairment: analysis from VISTA.

Acta neurologica Scandinavica·2016
Same journal

Human health in relation to visible, functional, and accessible green space: a systematic review and narrative synthesis of the 3 + 30 + 300 guideline.

British medical bulletin·2026
Same journal

Muscle herniae in exercise-induced leg pain: diagnostic pitfalls and the 'repair paradox'.

British medical bulletin·2026
Same journal

Scaffolds and platelet concentrates in bone regenerative medicine: applications, mechanisms, and future approaches.

British medical bulletin·2026
Same journal

Back squat and deadlift fatiguing protocols elicit distinct countermovement jump profiles: phase-specific predictors and soreness responses.

British medical bulletin·2026
Same journal

Enhancing bone healing through osteogenic medium components: biological roles, mechanisms, and clinical applications.

British medical bulletin·2026
Same journal

Moral injury in healthcare workers: causes & interventions.

British medical bulletin·2026
See all related articles

Area of Science:

  • Neuroscience
  • Pharmacology
  • Clinical Trials

Background:

  • Thrombolysis improves stroke outcomes but has limited patient applicability.
  • Neuroprotection presents a potential universal treatment strategy for stroke, applicable alone or with thrombolysis.
  • Existing neuroprotective agents have faced challenges in clinical trials due to issues with compound selection, dosage, and trial design.

Purpose of the Study:

  • To review the potential of neuroprotection as a stroke treatment.
  • To identify key molecular targets within neuroprotection strategies.
  • To discuss advancements in clinical trial methodologies for neuroprotective agents.

Main Methods:

  • Review of existing literature on neuroprotection in stroke.
  • Analysis of past clinical trial outcomes and identified limitations.

Related Experiment Videos

  • Discussion of emerging neuroprotective agents and advanced trial designs.

    • Main Results:

    • Several molecular pathways, including excitotoxicity and calcium signaling, are potential targets for neuroprotection.
    • Past clinical trials yielded disappointing results, often attributed to suboptimal drug choice, dosage, or trial design.
    • Newer trials are employing more selective agents and improved methodologies like computer randomization and diffusion-weighted MRI.

    Conclusions:

    • Despite past setbacks, the development of safe and effective neuroprotective treatments for stroke remains a strong possibility.
    • Advancements in drug development and clinical trial conduct are expected to improve the success rate of neuroprotective therapies.
    • The future prospects for improving stroke outcomes with neuroprotection are optimistic.